Table 5.
In-hospital bleeding complications
| Anticoagulation + Systemic alteplasea | Anticoagulation ± other therapiesb | Overall | |
|---|---|---|---|
| Total N (excluding supportive care only) | 13 | 411 | 423 |
| Cases with major + clinically relevant non-major bleedingc | 8 (61.5%) | 48 (11.7%) | 56 (13%) |
| Intracranial bleeding | 2 (15.4%) | – | 2 (0.47%) |
| Gastrointestinal | 3 (23%) | 12 (2.9%) | 15 (3.5%) |
| Hematuria | – | 9 (2.2%) | 9 (2.1%) |
| Surgical site | 1 (7.7%) | 7 (1.7%) | 8 (1.9%) |
| Soft tissue/intramuscular | – | 8 (1.9%) | 8 (1.9%) |
| Vascular access sites | 2 (15.4%) | – | 2 (0.47%) |
| Retroperitoneal | – | 2 (0.5%) | 2 (0.47%) |
| Hemoptysis | – | 2 (0.5%) | 2 (0.47%) |
aIncludes 3 patients managed on VA ECMO
bIncludes 1 patient with catheter-based thrombolysis and 1 with mechanical thrombectomy
cP < 0.001 by Chi-square 2-sample test for equality of proportions